{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:27:39Z","timestamp":1760189259986},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2012]]},"DOI":"10.2169\/internalmedicine.51.8005","type":"journal-article","created":{"date-parts":[[2012,8,13]],"date-time":"2012-08-13T22:40:50Z","timestamp":1344897650000},"page":"2125-2129","source":"Crossref","is-referenced-by-count":15,"title":["A Case of Intestinal Beh\u00e7et's Disease Treated with Infliximab Monotherapy Who Successfully Maintained Clinical Remission and Complete Mucosal Healing for Six Years"],"prefix":"10.2169","volume":"51","author":[{"given":"Yuriko","family":"Maruyama","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Keio University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Keio University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyoshi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Keio University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Naganuma","sequence":"additional","affiliation":[{"name":"Center for Diagnostic and Therapeutic Endoscopy, School of Medicine, Keio University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagamu","family":"Inoue","sequence":"additional","affiliation":[{"name":"Center for Diagnostic and Therapeutic Endoscopy, School of Medicine, Keio University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Ogata","sequence":"additional","affiliation":[{"name":"Center for Diagnostic and Therapeutic Endoscopy, School of Medicine, Keio University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Iwao","sequence":"additional","affiliation":[{"name":"Center for Preventive Medicine, School of Medicine, Keio University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Kanai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Keio University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Keio University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Garton RA, Ghate JV, Jorizzo JL. Behçet's disease. In: Textbook of Rheumatology. 7th ed. Harris ED Jr, Budd RC, Genovese MC, Firestein GS, Sargent JS, Sledge CB, Eds. Saunders, Philadelphia, 2005."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Krause I, Weinberger A. Behçet's disease. Curr Opin Rheumatol 20: 82-87, 2008, Review.","DOI":"10.1097\/BOR.0b013e3282f154d1"},{"key":"3","unstructured":"3. Sakane T, Takeno M, Suzuki N, Inaba G. Current concepts: Behçet disease. New Eng J Med 341: 1284-1291, 1999."},{"key":"4","unstructured":"4. Brandt LJ, Boley SJ. Intestinal ischemia. In: Gastrointestinal and Liver Disease. 7th ed. Feldman M, Friedman LS, Sleisenger MH, Eds. Saunders, Philadelphia, 2002."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach. J Gastroenterol 42: 737-745, 2007.","DOI":"10.1007\/s00535-007-2090-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 49: 725-728, 2001.","DOI":"10.1136\/gut.49.5.725"},{"key":"7","unstructured":"7. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 120: 995-999, 2001."},{"key":"8","unstructured":"8. Kram MT, May LD, Goodman S, Molinas S. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 46: 118-121, 2003."},{"key":"9","unstructured":"9. Byeon JS, Choi EK, Heo NY, et al. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case. Dis Colon Rectum 50: 672-676, 2007."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lee JH, Kim TN, Choi ST, et al. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med 22: 24-27, 2007.","DOI":"10.3904\/kjim.2007.22.1.24"},{"key":"11","unstructured":"11. Ju JH, Kwok SK, Seo SH, Yoon CH, Kim HY, Park SH. Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab. Clin Rheumatol 26: 1383-1385, 2007."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ugras M, Ertem D, Celikel C, Pehlivanoglu E. Infliximab as an alternative treatment for Behçet disease when other therapies fail. J Pediatr Gastroenterol Nutr 46: 212-215, 2008.","DOI":"10.1097\/MPG.0b013e3181346b60"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis 14: 1259-1264, 2008.","DOI":"10.1002\/ibd.20457"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Donghi D, Mainetti C. Infliximab for the treatment of refractory Adamantiades-Behçet disease with articular, intestinal, cerebral and ocular involvement. Dermatology 220: 282-286, 2010.","DOI":"10.1159\/000277928"},{"key":"15","unstructured":"15. Mizushima Y. Recent research into Behcet's disease in Japan. Int J Tissue React 10: 59-65, 1988."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Alexoudi I, Kapsimali V, Vaiopoulos A, Kanakis M, Vaiopoulos G. Evaluation of current therapeutic strategies in Behçet's disease. Clin Rheumatol 30: 157-163, 2011.","DOI":"10.1007\/s10067-010-1566-4"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behçet disease. J Clin Gastroenterol 30: e38-e45, 2012.","DOI":"10.1097\/MCG.0b013e3182431d56"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Naganuma M, Iwao Y, Inoue N, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behçet's disease. Am J Gastroenterol 95: 2848-2851, 2000.","DOI":"10.1016\/S0002-9270(00)01991-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Iida M, Kobayashi H, Matsumoto T, et al. Postoperative recurrence in patients with intestinal Behçet's disease. Dis Colon Rectum 37: 16-21, 1994.","DOI":"10.1007\/BF02047208"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Jung YS, Yoon JY, Lee JH, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behçet's disease. Inflamm Bowel Dis 17: 1594-1602, 2011.","DOI":"10.1002\/ibd.21517"},{"key":"21","unstructured":"21. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 28: 2010 [Epub ahead of print]."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362: 1383-1395, 2010.","DOI":"10.1056\/NEJMoa0904492"},{"key":"23","unstructured":"23. Van Assche G, Magdelaine-Beuzelin C, D'Haens G. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134: 1861-1868, 2008."},{"key":"24","unstructured":"24. Schnitzler F, Fidder H, Ferrante M. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58: 492-500, 2009."},{"key":"25","unstructured":"25. Ariyachaipanich A, Berkelhammer C, Nicola H. Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis 15: 1769-1771, 2009."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Iwata S, Saito K, Yamaoka K. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol 21: 184-191, 2011.","DOI":"10.1007\/s10165-010-0370-y"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/51\/16\/51_51.8005\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:45:12Z","timestamp":1621446312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/51\/16\/51_51.8005\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":26,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.51.8005","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}